TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Hangwen Li
Chairman and CEO at Stemirna Therapeutics

Profile

Having received his Ph.D degree from The University of Texas at Austin/MD Anderson Cancer Center, Dr. Hangwen Li has over 16 years of research experience in RNA biology,  cancer therapy and immunotherapy. Dr. Li has been awarded twice for the U.S. Department of Defense fellowship. He has also a joint faulty member including Roswell Park Cancer Center and Shanghai East Hospital of Tongji University.

Hangwen Li's Network

Agenda Sessions

  • Delivering of Novel Cure: Unbridling the Power of mRNA-based Medicines

    , 10:00
  • Delivering of Novel Cure: Unbridling the Power of mRNA-based Medicines

    , 10:00
  • Delivering of Novel Cure: Unbridling the Power of mRNA-based Medicines

    , 10:00

Speakers at this event